Please use this identifier to cite or link to this item:
|Title:||Early Phase II Study on BNCT in Metastatic Malignant Melanoma Using the Boron Carrier BPA (EORTC Protocol 11011)|
|Authors:||SAUERWEIN WOLFGANG; MOSS RAYMOND; STECHER-RASMUSSEN Finn; NIEVAART VICTOR ALEXANDER; GRABBE Stephan; HEIMANS Jan; COLLETTE Laurence; VAN LOENEN Arie; BUEHRMANN Sandra; ROCA ANTOANETA; HOVING Anton; RASSOW Juergen|
|Other Contributors:||WITTIG ANDREA|
|Citation:||Advances in Neutron Capture Therapy 2006 p. 284-287|
|Publisher:||International Society for Neutron Capture Therapy: ISNCT|
|JRC Publication N°:||JRC35042|
|Type:||Contributions to Conferences|
|Abstract:||The aim of the trial is to examine the clinical response of metastatic melanoma following BNCT with BPA. The trial contains an optional biodistribution sub-study , which is done if operable metastases are removed prior BNCT. BNCT is applied in 2 fractions at the HFR in Petten. In cases of diffuse brain metastases the whole brain is irradiated homogeneously using 5 irradiation beams from different directions. Up to now 4 patients suffering from multiple brain metastases (more than 20) have been included. In all cases we observed a partial response or no change in the irradiated volume. However, none of the patients survived more than 3 months. The pharmacokinetic of the BPA can be predicted very precisely using a two-compartment model. The treatment can be performed safely.|
|JRC Institute:||Institute for Energy and Transport|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.